AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36326117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of RAS inhibitors
Number of subjects: 411
Study 36326117 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of RAS inhibitors
Number of subjects: 411
Study 32217469 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function (EF) features
Number of subjects: 130
Study 32217469 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup identification via functional random forest (FRF)
Number of subjects: 130
Study 32217469 — intervention group
Group type: COMPARATOR
Intervention: Neuroimaging data
Number of subjects: 130
Study 35468091 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (remote monitoring with blood pressure monitor, weight scale, electrocardiogram device, step counter; two in-office visits replaced by e-visits)
Number of subjects: 0
Study 35468091 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up (control group)
Number of subjects: 0
Study 33872601 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone injected into masseter muscle
Number of subjects: 60
Study 33872601 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone injected into gluteal muscle
Number of subjects: 60
Study 33872601 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 60
Study 35017010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 infusion (2.5 pmol/kg/min)
Number of subjects: 21
Study 35017010 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 21
Study 34507060 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAHRP intervention
Number of subjects: 13914
Study 34507060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13914
Study 35776183 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 400
Study 35776183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 400
Study 33934468 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical treatment via direct leaf contact
Number of subjects: 2
Study 33934468 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical treatment via stem contact
Number of subjects: 2
Study 33934468 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical treatment at early growth stages (0.0125 W h)
Number of subjects: 2
Study 33934468 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical treatment at later growth stages (0.0125 W h)
Number of subjects: 2
Study 33934468 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical treatment at two-leaf growth stage (0.0025 W h)
Number of subjects: 2
Study 33934468 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysical treatment
Number of subjects: 2
Study 32734848 — intervention group
Group type: EXPERIMENTAL
Intervention: VCV-M infection confirmed by RT-PCR and western blot (WB) detection
Number of subjects: 17
Study 32734848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed viral infections detected through RT-PCR and ELISA
Number of subjects: 17
Study 32734848 — intervention group
Group type: EXPERIMENTAL
Intervention: Northern blot assay for confirmation of VCV-M infection
Number of subjects: 17
Study 36321229 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise group (IKE)
Number of subjects: 60
Study 36321229 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise group (CSE)
Number of subjects: 60
Study 36321229 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise group
Number of subjects: 60
Study 33939911 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic ASC (1 × 10^6 cells/kg) + cholecalciferol (2,000 UI/day) for 6 months
Number of subjects: 7
Study 33939911 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (group 2)
Number of subjects: 7
Study 33939911 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (group 3)
Number of subjects: 7
Study 32960178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile internet intervention for mothers and infants
Number of subjects: 86
Study 35101704 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA)
Number of subjects: 70
Study 35101704 — intervention group
Group type: COMPARATOR
Intervention: Sham thread embedding acupuncture (STEA)
Number of subjects: 70
Study 34654493 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine local infiltration
Number of subjects: 30
Study 34654493 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine inferior alveolar nerve block (IANB)
Number of subjects: 30
Study 33760691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (1:100,000)
Number of subjects: 31
Study 33760691 — intervention group
Group type: COMPARATOR
Intervention: Bacteriostatic normal saline
Number of subjects: 31
Study 33432600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 110
Study 33432600 — intervention group
Group type: COMPARATOR
Intervention: Semi-recumbent position
Number of subjects: 110
Study 34391744 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 34391744 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 34391744 — intervention group
Group type: EXPERIMENTAL
Intervention: TMVr
Number of subjects: 614
Study 35265370 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Progressive Addition Lenses (CPALs)
Number of subjects: 93
Study 35265370 — intervention group
Group type: COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Number of subjects: 93
Study 35852098 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with oral azacitidine (CC‐486) as maintenance therapy
Number of subjects: 0
Study 33787970 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based analysis with contrast-enhanced CT
Number of subjects: 23
Study 32791894 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/samidorphan combination
Number of subjects: 561
Study 32791894 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 561
Study 34980285 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 30
Study 34980285 — intervention group
Group type: EXPERIMENTAL
Intervention: ED PLUS
Number of subjects: 30
Study 34980285 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study 32613634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral passive stretching
Number of subjects: 39
Study 32613634 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolateral passive stretching
Number of subjects: 39
Study 32613634 — intervention group
Group type: COMPARATOR
Intervention: No passive stretching (control)
Number of subjects: 39
Study 36054086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral training (EXP)
Number of subjects: 60
Study 36054086 — intervention group
Group type: COMPARATOR
Intervention: Usual training schedule (CONT)
Number of subjects: 60
Study 33857594 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice nasal irrigation (LNI)
Number of subjects: 60
Study 33857594 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid nasal irrigation (CNI)
Number of subjects: 60
Study 33857594 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI)
Number of subjects: 60
Study 34034608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (diet and physical activity components) initiated in the first half of pregnancy, delivered through multiple modalities (in-person visits, telephone calls, text messages, email) by trained intervention staff (dietitian, lifestyle coach, physiotherapist).
Number of subjects: 4
Study 34034608 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth behavioral intervention for women with overweight or obesity.
Number of subjects: 4
Study 33009729 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivirals or treatment of complications (specifics not provided)
Number of subjects: 0
Study 33009729 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization's SOLIDARITY trial (specifics not provided)
Number of subjects: 0
Study 35577631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg +/‐ CpG1018
Number of subjects: 120
Study 35577631 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg alone
Number of subjects: 120
Study 35577631 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg alone
Number of subjects: 120
Study 35577631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32543080 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigone-sparing Botox injection (100 IU intradetrusal)
Number of subjects: 103
Study 32543080 — intervention group
Group type: COMPARATOR
Intervention: Trigone-involved Botox injection (100 IU intradetrusal)
Number of subjects: 103
Study 32543080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Trigone-sparing and Trigone-involved)
Number of subjects: 103
Study 32491154 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal influence
Number of subjects: 63
Study 32814520 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 289
Study 32814520 — intervention group
Group type: COMPARATOR
Intervention: Community controls with impaired FPG
Number of subjects: 289
Study 32814520 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 289
Study 36130749 — intervention group
Group type: EXPERIMENTAL
Intervention: Religion-adapted ApBM
Number of subjects: 120
Study 36130749 — intervention group
Group type: COMPARATOR
Intervention: Standard ApBM
Number of subjects: 120
Study 36130749 — intervention group
Group type: COMPARATOR
Intervention: Sham ApBM
Number of subjects: 120
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.125
Number of subjects: 100
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.200
Number of subjects: 100
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.250
Number of subjects: 100
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.300
Number of subjects: 100
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with voxel size 0.400
Number of subjects: 100
Study 33337942 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT scans with artifact reduction (AR)
Number of subjects: 100
Study 33337942 — intervention group
Group type: COMPARATOR
Intervention: CBCT scans without artifact reduction (AR)
Number of subjects: 100
Study 33571031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal individualized mixed management intervention (four sessions of psycho-education and breastfeeding education)
Number of subjects: 182
Study 33571031 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 33298104 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated maple sap (MW)
Number of subjects: 76
Study 33298104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted maple syrup (MS)
Number of subjects: 76
Study 33298104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; water sweetened with stevia)
Number of subjects: 76
Study 36341700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 80
Study 36341700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33517882 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional daily physical therapy focused on mobility (n=99)
Number of subjects: 198
Study 33517882 — intervention group
Group type: COMPARATOR
Intervention: Additional social activities (n=99)
Number of subjects: 198
Study 33517882 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional daily physical therapy focused on mobility
Number of subjects: 198
Study 37034563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 304
Study 37034563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 304
Study 37034563 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 304
Study 37034563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 304
Study 32956615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care, intravenous immunoglobulin, methylprednisolone, biological therapies (IL-1 antagonists, IL-6 receptor blockers, anti-TNF agents)
Number of subjects: 0
Study 32956615 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 antagonists (e.g., anakinra), IL-6 receptor blockers (e.g., tocilizumab), anti-TNF agents (e.g., infliximab)
Number of subjects: 0
Study 32956615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid online Delphi process
Number of subjects: 0
Study 32956615 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus statements
Number of subjects: 0
Study 32956615 — intervention group
Group type: EXPERIMENTAL
Intervention: New PIMS-TS specific treatment groups
Number of subjects: 0
Study 32484940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg/d
Number of subjects: 54
Study 32484940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg/d
Number of subjects: 54
Study 32484940 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) high doses (≥1000 μg BID)
Number of subjects: 54
Study 32484940 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) high doses (≥1500 μg BID)
Number of subjects: 54
Study 32484940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 54
Study 32484940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 54
Study 32484940 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 54
Study 35750598 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum chewing
Number of subjects: 69
Study 35750598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonxylitol gum chewing
Number of subjects: 69
Study 35750598 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 33261032 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg·kg−1 caffeine
Number of subjects: 12
Study 33261032 — intervention group
Group type: COMPARATOR
Intervention: Non-ergogenic placebo
Number of subjects: 12
Study 33261032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual task
Number of subjects: 12
Study 33261032 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 12
Study 36107516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance therapy using telerehabilitation (n = 9)
Number of subjects: 17
Study 36107516 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (n = 8)
Number of subjects: 17
Study 34119373 — intervention group
Group type: EXPERIMENTAL
Intervention: High mNUTRIC group (n = 46)
Number of subjects: 359
Study 34119373 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased calorie intake (per 20% increase) in high mNUTRIC group
Number of subjects: 359
Study 32058351 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional microphone
Number of subjects: 19
Study 32058351 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction
Number of subjects: 19
Study 32058351 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional microphone
Number of subjects: 19
Study 32058351 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction
Number of subjects: 19
Study 33073879 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 437
Study 33073879 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 437
Study 33073879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 32703634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg/day)
Number of subjects: 40
Study 32703634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34363617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg IV plus diphenhydramine 25 mg IV
Number of subjects: 127
Study 34363617 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone 1 mg IV
Number of subjects: 127
Study 32436772 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXTflex
Number of subjects: 0
Study 32436772 — intervention group
Group type: EXPERIMENTAL
Intervention: NEBNext
Number of subjects: 0
Study 32436772 — intervention group
Group type: EXPERIMENTAL
Intervention: QIAseq and TailorMix
Number of subjects: 0
Study 32436772 — intervention group
Group type: COMPARATOR
Intervention: Synthetic miRNAs and human RNA
Number of subjects: 0
Study 32142397 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner playing poorly
Number of subjects: 103
Study 32142397 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner having a good performance
Number of subjects: 103
Study 32142397 — intervention group
Group type: COMPARATOR
Intervention: Partner perceived as playing their usual game (control group)
Number of subjects: 103
Study 35487522 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 0
Study 35487522 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol cigarettes
Number of subjects: 0
Study 35487522 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol preference at baseline
Number of subjects: 0
Study 34463869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 608
Study 34463869 — intervention group
Group type: COMPARATOR
Intervention: Uracil-tegafur (UFT)
Number of subjects: 608
Study 32901739 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical simulation as an educational strategy
Number of subjects: 30
Study 32901739 — intervention group
Group type: COMPARATOR
Intervention: Usual class
Number of subjects: 30
Study 35334862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose whey protein concentrate (WPC)
Number of subjects: 121
Study 35334862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose whey protein concentrate (WPC)
Number of subjects: 121
Study 35334862 — intervention group
Group type: COMPARATOR
Intervention: Whey hydrolysate placebo
Number of subjects: 121
Study 34132448 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion observation therapy in virtual reality equipment combined with conventional cognitive training
Number of subjects: 118
Study 34132448 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 118
Study 32095914 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and economic equity
Number of subjects: 675
Study 32095914 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 675
Study 32095914 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from friends
Number of subjects: 675
Study 33200512 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 415
Study 33200512 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA)
Number of subjects: 415
Study 35693254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandplay (SP) therapy
Number of subjects: 34
Study 35693254 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 34
Study 33589135 — intervention group
Group type: EXPERIMENTAL
Intervention: Human endometrial biopsies
Number of subjects: 90
Study 32178766 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks
Number of subjects: 741
Study 32178766 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 741
Study 32178766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study 34642762 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amino acids (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Number of subjects: 24
Study 34642762 — intervention group
Group type: COMPARATOR
Intervention: Intact milk protein (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Number of subjects: 24
Study 34642762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both free amino acids and intact milk protein
Number of subjects: 24
Study 34516246 — intervention group
Group type: COMPARATOR
Intervention: MK-8507 (2 to 400 mg)
Number of subjects: 40
Study 34516246 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8507 (≥100 mg)
Number of subjects: 40
Study 34516246 — intervention group
Group type: COMPARATOR
Intervention: MK-8507 (400 mg once weekly)
Number of subjects: 40
Study 34516246 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple doses of MK-8507
Number of subjects: 40
Study 36253339 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage (5 weeks, daily for at least 10 minutes)
Number of subjects: 32
Study 36253339 — intervention group
Group type: COMPARATOR
Intervention: Control group (received intervention after study completion)
Number of subjects: 32
Study 33892135 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific cytotoxic T-lymphocytes (CMV-CTLs)
Number of subjects: 27
Study 33892135 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care therapy
Number of subjects: 27
Study 32948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-needle lavage (DNL)
Number of subjects: 100
Study 32948387 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-needle lavage (DNL) with 2 needles at upper and lower extremes (B2)
Number of subjects: 100
Study 32948387 — intervention group
Group type: COMPARATOR
Intervention: Single-needle aspiration (SNA)
Number of subjects: 100
Study 35793185 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB+G group (30 mL of 0.375% ropivacaine)
Number of subjects: 0
Study 35793185 — intervention group
Group type: COMPARATOR
Intervention: G group (30 mL of 0.9% saline)
Number of subjects: 0
Study 35793185 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB+G group
Number of subjects: 0
Study 35793185 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0